<code id='1DC8337E00'></code><style id='1DC8337E00'></style>
    • <acronym id='1DC8337E00'></acronym>
      <center id='1DC8337E00'><center id='1DC8337E00'><tfoot id='1DC8337E00'></tfoot></center><abbr id='1DC8337E00'><dir id='1DC8337E00'><tfoot id='1DC8337E00'></tfoot><noframes id='1DC8337E00'>

    • <optgroup id='1DC8337E00'><strike id='1DC8337E00'><sup id='1DC8337E00'></sup></strike><code id='1DC8337E00'></code></optgroup>
        1. <b id='1DC8337E00'><label id='1DC8337E00'><select id='1DC8337E00'><dt id='1DC8337E00'><span id='1DC8337E00'></span></dt></select></label></b><u id='1DC8337E00'></u>
          <i id='1DC8337E00'><strike id='1DC8337E00'><tt id='1DC8337E00'><pre id='1DC8337E00'></pre></tt></strike></i>

          Home / fashion / knowledge

          knowledge


          knowledge

          author:comprehensive    Page View:4244

          Editor’s note: A recording of the event is embedded below.

          After a few go-go years, the early-stage biotech market has cooled considerably. Two VCs will weigh in on what distinguishes great science from bad investments.

          advertisement

          Featured Speakers

          • Irena Melnikova, Ph.D., partner, Pfizer Ventures
          • Rakhshita Dhar, senior director, venture investments, Leaps by Bayer
          • Frank S. David, M.D., Ph.D., managing director, Pharmagellan (moderator)

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In